Hepatology
A topic in the Science corpus, drawn from 1,215 papers.
Trusted voices in Hepatology
Ordered by the trust Hepatology's own network concentrates on each researcher, most first.
- S. Friedman — trusted by 42 researchers here
- Jordi Bruix1 , 2 — trusted by 46 researchers here
- J. Llovet — trusted by 41 researchers here
- for the Statistics Subcommittee of the NCI—EORTC Worki Diagnostics — trusted by 13 researchers here
- E. Brunt — trusted by 24 researchers here
- R. Taub — trusted by 18 researchers here
- D. Lavanchy — trusted by 20 researchers here
- M. Pinzani — trusted by 20 researchers here
- H. B. EL‐SERAG — trusted by 20 researchers here
- J. Iredale — trusted by 11 researchers here
- Z. Younossi — trusted by 17 researchers here
- M. Sherman — trusted by 14 researchers here
Most-cited papers in Hepatology
Ordered by the recorded citation count from the source corpus; a citation is not an endorsement.
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease (2005, Hepatology) — 10,109 citations
- Management of hepatocellular carcinoma: An update (2011, Hepatology) — 8,421 citations
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, Journal of Hepatology) — 8,228 citations
- Sorafenib in advanced hepatocellular carcinoma. (2008, New England Journal of Medicine) — 7,076 citations
- Single Lgr5 stem cells build cryptvillus structures in vitro without a mesenchymal niche (2009, Nature) — 6,694 citations
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018, Hepatology) — 6,253 citations
- Sorafenib in advanced hepatocellular carcinoma. (2008, New England Journal of Medicine) — 6,212 citations
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. (2020, New England Journal of Medicine) — 5,608 citations
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (2009, The Lancet Oncology) — 5,311 citations
- Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group (2012, Critical Care) — 5,149 citations
- Incident reporting and patient safety (2007) — 5,142 citations
- Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. (2007, Gastroenterology) — 5,012 citations
- A model to predict survival in patients with end‐stage liver disease (2001, Hepatology) — 4,957 citations
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection (2006, Hepatology) — 4,602 citations
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. (2018, The Lancet) — 4,560 citations
- A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C (2003, Hepatology) — 4,446 citations
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. (2017, Journal of Hepatology) — 4,438 citations
- A human colon cancer cell capable of initiating tumour growth in immunodeficient mice (2007, Nature) — 4,313 citations
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma (2010, Seminars in liver disease (Print)) — 4,176 citations
- Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. (2001, Journal of Hepatology) — 4,137 citations
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance (2009, Nature) — 3,837 citations
- AASLD guidelines for the treatment of hepatocellular carcinoma (2018, Hepatology) — 3,751 citations
- Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity (2004, Hepatology) — 3,736 citations
- Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance (2018, Hepatology) — 3,704 citations
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial (2017, The Lancet) — 3,695 citations
- A global view of hepatocellular carcinoma: trends, risk, prevention and management (2019, Nature reviews: Gastroenterology & hepatology) — 3,633 citations
- EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, European Journal of Cancer) — 3,548 citations
- EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease (2016, Obesity Facts) — 3,531 citations
- Management of hepatocellular carcinoma (2005, Hepatology) — 3,455 citations
- Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. (2011, Gastroenterology) — 3,443 citations
- Diagnosis, management, and treatment of hepatitis C: An update (2009, Hepatology) — 3,377 citations
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. (2002, The Lancet) — 3,362 citations
- Burden of liver diseases in the world. (2019, Journal of Hepatology) — 3,240 citations
- Effect of pegylation on pharmaceuticals (2003, Nature reviews. Drug discovery) — 3,236 citations
- Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma (2012, Gastroenterology) — 3,218 citations
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017, The Lancet) — 3,215 citations
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, Annals of Oncology) — 3,178 citations
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2019, Clinical Liver Disease) — 3,139 citations
- Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. (2006, Journal of the American Medical Association (JAMA)) — 3,131 citations
- Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. (2006, Journal of Hepatology) — 3,082 citations
- Global epidemiology of hepatitis C virus infection. (2005, Lancet. Infectious Diseases (Print)) — 3,054 citations
- The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD (2007, Hepatology) — 3,034 citations
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis (2010, New England Journal of Medicine) — 3,032 citations
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy (2013, Nature reviews. Molecular cell biology) — 3,023 citations
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival (2003, Hepatology) — 3,017 citations
- Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. (2004, Annals of Internal Medicine) — 2,999 citations
- BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. (2021, Journal of Hepatology) — 2,982 citations
- Production of infectious hepatitis C virus in tissue culture from a cloned viral genome (2005, Nature Medicine) — 2,936 citations
- The natural history of nonalcoholic fatty liver disease: a population-based cohort study. (2005, Gastroenterology) — 2,924 citations
- Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. (2005, Gastroenterology) — 2,856 citations
Most active researchers
By papers in this topic: a volume measure, not trust.
- J. Llovet — 43 papers
- Jordi Bruix1 , 2 — 31 papers
- M. Kudo — 24 papers
- S. Friedman — 22 papers
- Z. Younossi — 21 papers
- A. Sanyal — 20 papers
- H. B. EL‐SERAG — 16 papers
- Kris V. Kowdley — 16 papers
- G. Garcia‐Tsao — 15 papers
- A. Cheng — 15 papers
- Andrew X. Zhu — 15 papers
- V. Mazzaferro — 15 papers